Limited role for fibroblast growth factor 23 in assessing prognosis in heart failure patients: data from the TIME-CHF trial

R. Stohr, V.M. Brandenburg, G.H. Heine, M.T. Maeder, G. Leibundgut, A. Schuh, U. Jeker, M. Pfisterer, S. Sanders-van Wijk, H.P. Brunner-La Rocca

Research output: Contribution to journalArticleAcademicpeer-review

9 Citations (Web of Science)
Original languageEnglish
Pages (from-to)701-709
Number of pages9
JournalEuropean journal of heart failure
Volume22
Issue number4
DOIs
Publication statusPublished - 1 Apr 2020

Keywords

  • associations
  • cardiovascular events
  • chronic kidney-disease
  • converting enzyme-inhibition
  • elderly-patients
  • fgf-23
  • fgf23
  • fibroblast growth factor 23
  • heart failure
  • hospitalisation
  • mortality
  • prognosis
  • risk
  • risk assessment
  • standard medical therapy
  • MORTALITY
  • Prognosis
  • Fibroblast growth factor 23
  • STANDARD MEDICAL THERAPY
  • CONVERTING ENZYME-INHIBITION
  • FGF-23
  • Risk assessment
  • FGF23
  • Hospitalisation
  • Heart failure
  • ASSOCIATIONS
  • CARDIOVASCULAR EVENTS
  • Mortality
  • RISK
  • CHRONIC KIDNEY-DISEASE
  • ELDERLY-PATIENTS

Cite this